2-(aminomethyl)-4-fluorophenol

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(aminomethyl)-4-fluorophenol
• 化学式: C₇H₈FNO
• 分子量: 141.145
• InChiKey: UYMVQJOKMVAUIS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.14
• 拓扑面积：
  46.2
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-(aminomethyl)-4-fluorophenol 在 sodium carbonate 、 N,N-二异丙基乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 水 、 丙酮 、 乙腈 为溶剂， 生成 1-(2-(2-morpholinopyrimidin-4-yloxy)-5-fluorobenzyl)-3-(3-t-butyl-1-p-tolyl-1H-pyrazol-5-yl)urea
  参考文献：
  名称：

  Design and synthesis of novel p38α MAP kinase inhibitors: Discovery of pyrazole-benzyl ureas bearing 2-molpholinopyrimidine moiety

  摘要：

  The discovery that pyrazole-benzyl urea derivatives bearing a 2-molpholinopyrimidine moiety are novel p38 alpha inhibitors is described. A comparative view of the binding modes of SB-203580 and BIRB-796 by structural alignment of two X-ray co-crystal structures was utilized to identify this novel series. Modification of the benzyl group led to compound 2b, a highly potent p38 alpha inhibitor. In in vivo studies, 2b inhibited the production of tumor necrosis factor-alpha in lipopolysaccharide-treated mouse in a dose-dependent manner. Furthermore, the results of a 5-day repeated oral dose toxicity study suggest that 2b has low hepatotoxicity. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.05.095
• 作为产物：
  描述：

  5-fluoro-2-hydroxybenzaldehyde oxime 在 sodium amalgam 、 5% Rh/C 、 水 作用下， 生成 2-(aminomethyl)-4-fluorophenol
  参考文献：
  名称：

  来自 6-苄氨基嘌呤的细胞分裂素受体拮抗剂

  摘要：

  最近我们报道了 6-(2-hydroxy-3-methylbenzylamino)purine (PI-55) 作为第一个在受体水平拮抗细胞分裂素活性的分子。在这里，我们报告了在苄基环和嘌呤部分的 C2、N7 和 N9 位置取代的 11 种 BAP 衍生物的合成和体外生物测试。这些化合物与拟南芥细胞分裂素受体 AHK3 和 CRE1/AHK4 相互作用的能力在细菌受体和活细胞结合试验中以及在拟南芥 ARR5:GUS（拟南芥反应调节剂 5）报告基因试验中进行了测试。在经典的细胞分裂素生物测试（烟草愈伤组织、小麦叶衰老和苋属植物生物测定）中测定了化合物的细胞分裂素活性。6-(2,5-Dihydroxybenzylamino)purine (LGR-991) 被鉴定为细胞分裂素受体拮抗剂。在分子水平上，LGR-991 以与 PI-55 相同的效力阻断细胞分裂素受体 CRE1/AHK4。此外，LGR-991

  DOI：

  10.1016/j.phytochem.2010.01.018

文献信息

• Substituted 6-(Benzylamino) Purine Riboside Derivatives, Use Thereof and Compositions Containing These Derivatives
  申请人：Szucova Lucie

  公开号：US20120071433A1

  公开（公告）日：2012-03-22

  The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.

  该发明涉及一般式I的2-取代-6-(取代苯基氨基)嘌呤核苷衍生物。这些化合物具有抗凋亡、抗炎和分化活性。该发明还涉及包含这些衍生物作为活性成分的组合物。
• SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5' -MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATIONS CONTAINING THESE COMPOUNDS
  申请人：Zatloukal Marek

  公开号：US20130040908A1

  公开（公告）日：2013-02-14

  Substitution derivatives of N 6 -benzyladenosine-5′-monophosphate of the general formula I, wherein (R) n represents 1 to 4 substituents (n is in the range 1-4), which can be the same or different, and R is selected from the group comprising C 1 to C 8 alkyl, C 1 to C 8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. A Method for their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives is also disclosed.

  通式I的N6-苄基腺苷-5'-磷酸的取代衍生物，其中（R）n表示1至4个取代基（n在1-4范围内），可以相同也可以不同，R选自包括C1到C8烷基，C1到C8烷氧基，氨基，卤素，羟基，巯基和硝基基团的群体，并且其药用盐。还公开了它们的制备方法，作为药物和其他应用中的使用，以及含有这些衍生物的治疗组合物。
• [EN] CHIRAL DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES<br/>[FR] MACROCYCLES DE DIARYLE CHIRAUX À UTILISER EN TANT QUE MODULATEURS DE PROTÉINES KINASES
  申请人：TP THERAPEUTICS INC

  公开号：WO2017004342A1

  公开（公告）日：2017-01-05

  The present disclosure relates to certain chiral diaryl macrocyclic derivatives, pharmaceutical compositions containing them, and methods of using them to treat cancer, pain, neurological diseases, autoimmune diseases, and inflammation.

  本公开涉及特定手性二芳基大环衍生物，包含它们的药物组合物，以及使用它们治疗癌症、疼痛、神经系统疾病、自身免疫疾病和炎症的方法。
• [EN] 5,7-DISUBSTITUTED 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES FOR USE AS MEDICAMENTS AND PHARMACEUTICAL COMPOSITIONS<br/>[FR] 3-ISOPROPYLPYRAZOLO[4,3-D]PYRIMIDINES 5,7-DISUBSTITUÉES DESTINÉES À ÊTRE UTILISÉES À TITRE DE MÉDICAMENTS ET COMPOSITIONS PHARMACEUTIQUES
  申请人：C3 BIO GMBH

  公开号：WO2010139288A1

  公开（公告）日：2010-12-09

  This technical solution relates to 5,7-disubstituted 3-isopropylpyrazolo[4,3-d]pyrimidine derivatives for inhibiting proliferation and inducing apoptosis in mammalian cells, in particular for preventing, inhibiting and/or treating abnormal vascular smooth muscle cell (VSMC) proliferation and specifically in preventing, inhibiting or treating restenosis. It further concerns pharmaceutical compositions containing said derivatives.

  这项技术解决方案涉及用于抑制哺乳动物细胞增殖并诱导凋亡的5,7-二取代3-异丙基吡唑并[4,3-d]嘧啶衍生物，特别用于预防、抑制和/或治疗异常的血管平滑肌细胞（VSMC）增殖，特别是用于预防、抑制或治疗再狭窄。此外还涉及含有上述衍生物的药物组合物。
• Discussion of the proton potential with proton-transfer equilibria: thermodynamic data and infrared continua as a function of temperature
  作者：Rainer Krämer、Georg Zundel、Bogumił Brzezinski、Jerzy Olejnik

  DOI：10.1039/ft9928801659

  日期：——

  The infrared continua caused with intramolecular hydrogen bonds of the type AH⋯B ⇌ A–⋯H+B have been studied as a function of the ΔpKa of the hydrogen-bond donor and acceptor as well as a function of the temperature. From the behaviour of these continua it is shown that the shape of the proton potential may change with decreasing temperature from a double minimum with the deeper well at the donor to proton potential with the deeper well at the acceptor. The In (KPT) over 1/T plots result, however, always in negative apparent ‘ΔH° values’. Hence with all such proton-transfer hydrogen bonds the deeper well of the double-minimum proton potentials should always be at the acceptor group.Using the reaction-field theory, it is shown that for proton-transfer equilibria the slope of these In KPT vs. 1/T plots remains linear since ∂P/∂T, i.e. the derivative of the Onsager parameter P against the temperature T is constant if it is considered with not too large a temperature range, and since ΔH° changes with temperature by a term which is linear in T. Therefore, from the In (KPT)vs. 1/T plots apparent ‘ΔH° values’ are obtained from which the true values can be calculated if ∂P/∂T is known.

  我们研究了分子内氢键 AH⋯B ⇌ A-⋯H+B 类型引起的红外连续波，它是氢键供体和受体的 ΔpKa 的函数，也是温度的函数。这些连续曲线的行为表明，质子势的形状可能会随着温度的降低而改变，从供体处较深井的双最小值变为受体处较深井的质子势。然而，In (KPT) over 1/T 图的结果总是负的表观 "ΔH° 值"。因此，在所有这类质子转移氢键中，双最小质子势的深井应始终位于受体基团。利用反应场理论可以证明，对于质子转移平衡，由于 ∂P/∂T，即 Onsager 参数的导数，In KPT vs. 1/T 图的斜率保持线性。因此，从 In (KPT)vs. 1/T 图中可以得到明显的 "ΔH° 值"，如果知道 ∂P/∂T，就可以从中计算出真实值。